Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
18.07
+1.90 (11.75%)
At close: Jul 30, 2026, 4:00 PM EDT
18.07
0.00 (0.00%)
After-hours: Jul 30, 2026, 4:10 PM EDT

Anika Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
120.65112.82119.91120.79113.83147.79
Revenue Growth
5.33%-5.91%-0.73%6.12%-22.98%13.29%
Cost of Revenue
45.6549.0143.9138.2640.6164.85
Gross Profit
7563.817682.5373.2282.94
Selling, General & Admin
52.6749.0955.5659.9351.2374.1
Research & Development
27.4525.7725.5421.7618.3227.33
Other Operating Expenses
-0000-21.1
Total Operating Expenses
80.1374.8681.181.6969.5580.33
Operating Income
-5.12-11.05-5.10.843.672.62
Interest Income
2.211.742.342.310.65-0.19
Total Non-Operating Income (Expense)
2.211.742.342.310.65-0.19
Pretax Income
-2.91-9.31-2.763.164.322.43
Provision for Income Taxes
0.210.676.066.62.12-1.71
Net Income
-3.12-9.98-8.83-3.442.24.13
Earnings From Discontinued Operations
-0.66-0.9-47.56-79.23-17.06-
Net Income to Common
-3.78-10.88-56.39-82.67-14.864.13
Net Income Growth
------
Shares Outstanding (Basic)
141415151514
Shares Outstanding (Diluted)
141415151515
Shares Change
-3.14%-2.60%0.44%-0.89%1.05%2.90%
EPS (Basic)
-0.15-0.70-0.60-0.230.150.29
EPS (Diluted)
-0.17-0.70-0.60-0.230.150.28
EPS Growth
-----46.43%-
Free Cash Flow
0.564.36-2.33-7.22-3.083.25
Free Cash Flow Growth
------71.55%
Free Cash Flow Per Share
0.040.30-0.16-0.49-0.210.22
Gross Margin
62.16%56.56%63.38%68.33%64.33%56.12%
Operating Margin
-4.24%-9.80%-4.25%0.70%3.22%1.77%
Profit Margin
-2.59%-8.85%-7.36%-2.85%1.93%2.80%
FCF Margin
0.47%3.87%-1.94%-5.97%-2.70%2.20%
EBITDA
0.51-5.323.0215.0618.1623.4
EBITDA Margin
0.42%-4.72%2.52%12.47%15.95%15.83%
EBIT
-5.12-11.05-5.10.843.672.62
EBIT Margin
-4.24%-9.80%-4.25%0.70%3.22%1.77%
Effective Tax Rate
-7.14%-7.22%-219.39%208.97%49.12%-70.33%
SEC Filings: 10-K · 10-Q